“…However, there are no validated clinicopathologic or biomarkers to help risk stratify patients with metastatic disease. Existing data, largely limited to population level registries, have identified several poor prognostic factors, including advanced age, male gender, poor Eastern Cooperative Oncology Group performance status (ECOG PS), primary tumor location, and presence of peritoneal metastasis [ 3 , 17 , 18 , 19 , 20 ]. Younger age, female gender, good performance status at diagnosis, and treatment with palliative chemotherapy have been associated with improved survival [ 20 , 21 ].…”